3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow BIIB022: new trials by email Literature Review of BIIB022 trials Research Report on BIIB022
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer BIIB022 With Paclitaxel and Carboplatin - Non-Small Cell Lung Cancer | Phase 1 | Completed | Biogen | 18 | 2009-10-01 | 2013-09-16 |
| Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) BIIB022, Sorafenib - Hepatocellular Carcinoma | Phase 1 | Completed | Biogen | 40 | 2009-08-01 | 2013-09-16 |
| Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors BIIB022 - Solid Tumors | Phase 1 | Completed | Biogen | 40 | 2008-01-01 | 2017-01-09 |
Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Insulin-Like Growth Factor I, Resistance To (1) · Liver Neoplasms (1) · Recurrence (1)
Biogen (3)
United States (3) · Singapore (1) · Taiwan (1) · United Kingdom (1)